

# 5

## References

- Abbott A (2005). Europe pares down double patents on breast-cancer gene. *Nature*, 26 January 2005, 433(7024):344.
- Adewole TA, et al.(1999). Application of polymerase chain reaction to the prenatal diagnosis of sickle cell anaemia in Nigeria. *West African Journal of Medicine*, 1999, 18(3):160–165.
- Ahmed S, et al. (2002). Screening extended families for genetic haemoglobin disorders in Pakistan. *New England Journal of Medicine*, 347(15):1162–1168.
- Altonn H (2002). UH makes gene patent history. *Star-bulletin*, 23 December 2002 (<http://starbulletin.com/2002/12/23/news/story7.html>, accessed 7 March 2004).
- Alwan A, Modell B (2003). Opinion: Recommendations for introducing genetics services in developing countries. *Nature Reviews: Genetics*, 2003, 4(1):61–68.
- Andrews LB, Mehlman MJ, Rothstein MA, eds (2002). Chapter 5: Commercialization of genetic research: Property, patents, and conflicts of interest. In: *Genetics: Ethics, Law and Policy*. St. Paul, Mn., West Group, 2002.
- Barbosa DB (2004). The New Brazilian Patent Law (<http://www.nbb.com.br/public/memos5.htm>, accessed 2 March 2004).
- Bar-Shalom A, Cook-Deegan R (2002). Patents and innovation in cancer therapeutics: Lessons from CellPro. *The Milbank Quarterly*, 2002, 80(4):637–676.
- Benkler Y (2004). Commons-based strategies and the problems of patents. *Science*, 305(5687):1110–1111.
- Berg K et al. (2000) Genetic benefit sharing. *Science*, 6 October 2000:49.
- Berne Declaration (2003).
- Biological Procedures Online (2004). Announcement of the chicken genome sequence and genome variation maps. *Biological Procedures Online* (<http://www.biologicalprocedures.com/bpo/general/news/040301/05.htm>, accessed 5 March 2004).
- BioSpectrum (2003). Biotech industry outlook. Biospectrum India (<http://www.biospectrumindia.com/advertising/bs.asp> accessed 22 February 2005).
- Bosch X (2004). Myriad loses rights to breast cancer gene patent. *Lancet*, 2004, 363(9423):1780.
- Boyle J (2003). The second enclosure movement and the construction of the public domain. *Law and Contemporary Problems*. Winter/Spring, 66(1&2):33–74.
- Brazil Law (1996). Law No.9.279/96.
- Brower V (2000). Canavan families slam scientists over test patent profits. *Biotechnology News*, 2000:1.
- Brower V (2001). Tackling the most difficult diseases: Genetics and genomics open new strategies to fight vector-borne diseases.

- EMBO Reports*, 2001, October, 2(10):875–877.
- Brown MS, Ho YK, Goldstein JL (1976). The low-density lipoprotein pathway in human fibroblasts: relation between cell surface receptor binding and endocytosis of low-density lipoprotein. *Annals of the New York Academy of Sciences*, 1976, 275:244–257.
- Cahill LS (2001). Genetics, commodification, and social justice in the globalisation era. *Kennedy Institute of Ethics Journal*, 2001, 11(3):221.
- Cao A et al. (2002). Screening for thalassemia: A model of success. *Obstetric and Gynecology Clinics of North America*, June 2002, 29(2):305–28 (vi–vii).
- Carroll AE (1995). A review of recent decisions of the United States Court of Appeals for the Federal Circuit: Comment: Not always the best medicine: Biotechnology and the global impact of U.S. Patent Law. *The American University Law Review*, 1995, 44:2433.
- Check E (2002). Canada stops Harvard's oncomouse in its tracks. *Nature*, 12 December, 420(6916):593.
- China Daily* (2002). New patent rules to up standards. 2 September 2002 (<http://www.china.org.cn/english/MATERIAL/21876.htm>, accessed 6 March 2004).
- Cho MK et al. (2003). Effects of patents and licenses on the provision of clinical genetic testing services. *Journal of Molecular Diagnosis*, February 2003, 5(1):3–8.
- Clark J, et al (2000). Patent pools: A solution to the problem of access in biotechnology patents? 5 December 2000:1–16 (<http://www.uspto.gov/offices/pac/dapp/opla/patentpool.pdf>, accessed 2 July 2004).
- Clegg JB, Weatherall DJ (1999). Thalassemia and malaria: New insights into an old problem. *Proceedings of the Association of American Physicians*, 1999, July–August, 111(4):278–282.
- Coghlan A (2001). Patient power. *New Scientist*, 2001, 24 February 24 ([http://www.pxe.org/news/newscientist\\_022401.html](http://www.pxe.org/news/newscientist_022401.html), accessed 9 July 2004).
- Cogswell ME et al. (1999). Screening for hemochromatosis: A public health perspective. *American Journal of Preventive Medicine*, February, 16(2):134:140.
- Cohn A (2003). Now more common in non-Jews: Years of genetic testing virtually erase Tay-Sachs. *Jewish Bulletin News*, June 2003 (<http://www.jewishsf.com/bk030613/1b.shtml>, accessed 7 March 2004).
- Connor S (2003). Glaxo chief: Our drugs do not work on most patients. *Independent*, 8 December 2003 (<http://209.157.64.200/focus/f-news/1035880/posts>, accessed 19 February 2005).
- Cook-Deegan R, Chan C, A Johnson (2000). World survey on funding for genomics research. September 2000 (<http://www.stanford.edu/class/siw198q/websites/genomics/entry.htm>, accessed 9 March 2004).
- Cooper H (2001). White House drops WTO claim against Brazilian Patent Law. *Wall Street Journal*, 26 June 2001.
- Cornish WR, Llewelyn M, Adcock M (2003). *Intellectual Property Rights (IPRs) and genetics: A study into the impact and management of Intellectual Property Rights with the healthcare sector*. Cambridge, Public Health Genetics Unit, 2003.
- Cox SM et al. (2003). International genetic testing. *Genetic Medicine*, 2003, May–June, 5(3):176–182.
- Cukier KN (2003). Open source biotech. *Acumen Journal of Life Sciences*, 2003, I:3.
- da Graça Derengowski Fonseca M, da Silveira JMFJ (2002). *Frontiers of Innovation Research and Policy* (a Workshop between the Instituto de Economia—UFRJ, Brazil and CRIC/University of Manchester), September 2002,

- Rio de Janeiro, Brazil (<http://les1.man.ac.uk/cric/workshops/frontiers/papers.htm>, accessed 3 March 2004; paper available at <http://les1.man.ac.uk/cric/workshops/frontiers/papers/fonseca.pdf>, accessed 3 March 2004).
- Dalton R (2004). Bioprospectors edge towards deal with developing countries. *Nature*, 26 February 2004, 427:769.
- Devanand CJ, Schlich GW (2003). Is there a future for “speculative” gene patents in Europe? *Nature Reviews*, May 2003, 2:407.
- Diamond v. Chakrabarty* (1980), 447 U.S.
- DiMasi JA, Harsen RW, Gatowski HG (2003). The price of innovation, new estimates of drug development costs. *Journal of Health Economics*, 2003, 885:1–35.
- EC (1998). European Parliament and Council of European Union. Directive 98/44/EC of the European Parliament and of the Council. *Official Journal of the European Communities*, L 213/13, 30.7.98.
- EC (2004). *Results of the Competitiveness Council of Ministers*. Brussels, 11th March 2004, Internal Market, Enterprise and Consumer Protection issues. Brussels, 12 March 2004 (<http://europa.eu.int/rapid/pressReleasesAction.do?reference=MEMO/04/58&format=HTML&aged=0&language=EN&guiLanguage=en> accessed 22 June 2004).
- Economic and Social Council (2002). *Capacity of the public sector to support the creation and application of knowledge, innovation and technology for development*. Report of the Secretariat. 10 May 2002 (E/C.16/2002/5).
- Economist (2000). Science and technology: Fruits of co-operation. *The Economist* (London), 22 July 2000, 356(8180):79.
- Eisenberg R (2001). The shifting functional balance of patents and drug regulation. *Health Affairs*, September–October 2001.
- Eisenberg RS (2002a). Concerns about the patenting of genes. In: Andrews LB, Mehlman MJ, Rothstein MA, eds, *Genetics: Ethics, Law and Policy*. St. Paul, Mn., West Group, 2002:169–172.
- Eisenberg RS (2002b). Why the gene patenting controversy persists. *Academic Medicine*, 2002, 77(12):1381–1387.
- ETC Group (2004). From global enclosure to self enclosure: Ten years after – A critique of the CBD and the Bonn Guidelines on Access and Benefit Sharing. *Communiqué*, Issue 83, February 2004 ([http://www.etcgroup.org/documents/Comm83\\_COP7\\_CBDCBonn.pdf](http://www.etcgroup.org/documents/Comm83_COP7_CBDCBonn.pdf) accessed 20 March 2004).
- FDA (2004). *Challenge and opportunity on the critical path to new medical products*. Washington, DC, United States Department of Health and Human Services, Food and Drug Administration, 16 March 2004.
- Feng Z (2003). Rules set for study on genetic resources. *China Daily* (HK Edition), 25 November 2003.
- Finkel E (1999). Australian center develops tools for the developing world. *Science*, September 1999, 285:3.
- Fleishmann RD et al. (1995). Whole-genome random sequencing and assembly of *Haemophilus influenzae*. *Science*, 28 July 1995, 269:496–512.
- Gibbs RA, et al. (2004). Genome sequence of the brown Norway rat yields insights into mammalian evolution. *Nature*, 2004, 428(6982):493–521.
- Gold ER (2003). Exclusive rights in life: Biotechnology, genetic manipulation, and Intellectual Property Rights. In: Jackson JF, Linskens, HF, eds, *Molecular methods of plant analysis, vol. 23, Genetic transformation of plants*. New York, Springer, 2003:1–22.

- GRAIN (2002). *WIPO moves towards "World" patent*. Genetic Resource Action International (GRAIN), July 2002 (<http://www.grain.org/publications/wipo-patent-2002-en.cfm>, accessed 2 March 2004).
- Guttmacher AE, Collins FS (2002). Genomic medicine—a primer. *New England Journal of Medicine*, 7 November 2002, 347(19):1512–1520.
- Hall N et al. (2002). Sequence of *Plasmodium falciparum* chromosomes 1, 3–9 and 13. *Nature*, 2002, 419(6906):527–531.
- Hardin G (1968). The tragedy of the commons. *Science*, 162:1243–1248.
- Heller MA, Eisenberg RS (1998). Can patents deter innovation? The Anticommons in biomedical research. *Science*, 1 May 1998, 280:698–701.
- Howard K (2004). University entrepreneur initiatives on the rise. *Nature Biotechnology*, 2004, 22(5):625–626.
- International Human Genome Mapping Consortium (2001). A physical map of the human genome. *Nature*, 15 February 2001, 409(6822):934–41.
- IPR Commission (2002). *Integrating Intellectual Property Rights and Development Policy*. London, United Kingdom, Commission on Intellectual Property Rights, 2002:127 ([http://www.iprcommission.org/papers/pdfs/final\\_report/CIPRfullfinal.pdf](http://www.iprcommission.org/papers/pdfs/final_report/CIPRfullfinal.pdf), accessed 29 December 2003).
- Jimenez-Sanchez G (2003). Developing a platform for genomic medicine in Mexico. *Science*, 11 April 2003, 300(5617):295–296.
- Kaplan F (1998). Tay-Sachs disease carrier screening: A model for prevention of genetic disease. *Genetic Testing*, 1998, 2(4):271–292.
- Khoury MJ (2003). Genetics and genomics in practice: The continuum from genetic disease to genetic information in health and disease. *Genetic Medicine*, July–August 2003, 5(4):261–268.
- Kirby M (2002). *Report of the IBC on ethics, intellectual property and genomics*. Paris, International Bioethics Committee, UNESCO, January 2002 ([http://portal.unesco.org/shs/en/file\\_download.php/0f8d8bed17083342b45db84beef431ac](http://portal.unesco.org/shs/en/file_download.php/0f8d8bed17083342b45db84beef431ac) FinalReportIP\_en.pdf, accessed 4 January 2004).
- Kluge E-HW (2003). Patenting human genes: When economic interests trump logic and ethic. *Health Care Analysis*, June 2003, 11(2):119–130.
- Knoppers BM (1999). Status, sale and patenting of human genetic material: An international survey. *Nature Genetics*, May 1999, 22:23–26.
- Lecrubier A (2002). Patents and public health. *European Molecular Biology Organization Reports*, 2002, 3(12):1120–1122.
- Lewis R (2000). Clinton, Blair stoke debate on gene data: US–UK joint statement creates initial stir among commercial interests. *The Scientist*, 3 April 2000, 14(7):1.
- Mabey D et al. (2004). Diagnostics for the developing world. *Nature Reviews*, March 2004, 2:231–240.
- Madey v. Duke University* (2002). 307 F3d 1351 (Federal Circuit Court of Appeal 2002).
- Malakoff D (2004). NIH roils academe with advice on licensing DNA patents. *Science*, 2004, 303:1757–1758.

- Marks D, Thorogood M et al. (2003). A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis*, May 2003, 168(1):1–14.
- Marshall E (2000). Families sue hospital, scientist for control of Canavan gene. *Science*, 2000, 290(5494):1062.
- Marshall E (2004). Patient advocate named co-inventor on patent for the PXE disease gene. *Science*, 27 August 2004, 305:1226.
- Merz JF et al. (2002). Diagnostic testing fails the test: The pitfalls of patents are illustrated by the case of haemochromatosis. *Nature*, 7 February 2002, 415:577–579.
- Ministry of Health and Long-Term Care (2002). Genetic, testing and gene patenting: Charting new territory in healthcare. Toronto, Ontario, Ministry of Health and Long-Term Care, 2002 ([http://www.health.gov.on.ca/english/public/pub/ministry\\_reports/geneticsrep02/report\\_e.pdf](http://www.health.gov.on.ca/english/public/pub/ministry_reports/geneticsrep02/report_e.pdf), accessed 29 December 2003).
- Moukheiber Z (2003). Junkyard dogs. *Forbes*, 6 October 2003.
- Musungu SF, Dutfield G (2003). Multilateral agreements and a TRIPS-plus world. The World Intellectual Property Organisation (WIPO), Ottawa, 2003 (TRIPS Issues Paper No. 3).
- Nuffield (2002). *The ethics of patenting DNA, A discussion paper*. London, Nuffield Council on Bioethics, July 2002 (<http://www.nuffieldbioethics.org/filelibrary/pdf/theethicsofpatentingdna.pdf>, accessed 29 December 2003).
- OECD (2004). *Patents and innovation: Trends and policy challenges*. Paris, Organisation for Economic Co-operation and Development (<http://www.oecd.org/dataoecd/48/12/24508541.pdf> accessed 18 February 2005).
- Ogbu O (2002). African Science and Technology Day: Has Africa surrendered in the field of science and technology? *Science and Development in Africa*, 2002 (<http://www.sciencenewsdev.co.ke/special-f.htm>, accessed 19 December 2003).
- Oxfam (2001). *WTO patent rules and access to medicines: The pressure mounts*. Oxford, June 2001 ([http://www.oxfam.org.uk/what\\_we\\_do/issues/health/wto\\_patentrules.htm](http://www.oxfam.org.uk/what_we_do/issues/health/wto_patentrules.htm), accessed 19 February 2005).
- People's Daily (2001). Chinese firms keen on patent application for WTO entry. *People's Daily*, 15 August 2001 ([http://fpeng.peopledaily.com.cn/200108/15/eng20010815\\_77382.html](http://fpeng.peopledaily.com.cn/200108/15/eng20010815_77382.html), accessed 6 March 2004).
- Pharmaceutical Executive (2005). January 2005:S5 ([http://www.inmegen.org.mx/Portal/Pharmaceutical\\_Executive/Articulo\\_P\\_E.pdf](http://www.inmegen.org.mx/Portal/Pharmaceutical_Executive/Articulo_P_E.pdf), accessed 29 March 2005).
- Rai AK (1999). Intellectual property rights in biotechnology: Addressing new technology. *Wake Forest Law Review*, Fall 1999, 34:827–847.
- Rai AK (2004). Proprietary rights and collective action: The case of biotechnology research with low commercial value. Manuscript provided by author, 2004.
- Ramírez JL, Holmes D (2003). The need for genomics networking in Latin America. *SciDevNet*, 14 August 2003.
- Rausch LM (2002). International patenting of human DNA sequences. *InfoBrief*. National Science Foundation, August 2002.

- Read TD et al. (2000). Genome sequences of *Chlamydia trachomatis* MoPn and *Chlamydia pneumoniae* AR39. *Nucleic Acids Research*, 2000, 28:137–1406.
- Reichman JH, Lewis T (2005). Using liability rules to stimulate innovation in developing countries: Application to traditional knowledge. In: Maskus KE, Reichman JH, eds, *International public goods and transfer of technology under a globalized intellectual property regime*. Cambridge University Press (forthcoming 2005).
- Richards J (2002). Introduction. *Petty patent protection*. Ladas & Perry, 2002 ([http://www.ladas.com/Patents/PatentPractice/PettyPatents/PettyP\\_c.html](http://www.ladas.com/Patents/PatentPractice/PettyPatents/PettyP_c.html), accessed 3 March 2004).
- Rother L (2001). Model for research rises in a Third World city. *New York Times*, 1 May 2001.
- Scassa T (2003). A mouse is a mouse is a mouse: A comment on the Supreme Court of Canada's decision on the Harvard Mouse Patent. *Oxford University Commonwealth Law Journal*, 2003, Summer.
- Scherer FM (2002). The economics of human gene patents. *Academic Medicine*, December 2002, 77(12 Pt 2):1348–1367.
- Science and Engineering Indicators* (2002a). International patenting trends in two new technology areas (<http://www.nsf.gov/sbe/srs/seind02/c6/c6s5.htm#fn37>, accessed 6 March 2004).
- Science and Engineering Indicators* (2002b). Human DNA sequence patents: Number of international patent families, by priority country and priority year (<http://www.nsf.gov/sbe/srs/seind02/append/c6/at06-15.xls>, accessed 6 March 2004).
- Secretary's Advisory Committee on Genetic Testing (2000). *Summary of Panel Session on Human Gene Patenting and Licensing Practices and Access to Genetic Tests*, 7 June 2000, vol. 3 ([http://www4.od.nih.gov/oba/sacgt/reports/patent\\_panel\\_sum.pdf](http://www4.od.nih.gov/oba/sacgt/reports/patent_panel_sum.pdf) accessed 18 February 2005).
- Service R (2003). Genetics and medicine: Recruiting genes, proteins for a revolution in diagnostics. *Science*, 11 April 2003, 300(5617):236–239.
- Service R (2004). Incyte throws in the towel on genomics, trims workforce. *Science*, 13 February 2004, 303:941.
- Simpson A et al. (2000). The genome sequence of the plant pathogen *Xylella fastidiosa*. *Nature*, 13 July 2000, 406(6792):151–157.
- Singh G, Agarwal P (2003). Forward and backwards on patent law. *The Hindu Business Line*, 4 October 2003 (<http://www.blonet.com/2003/10/04/stories/2003100400090800.htm>, accessed 18 February 2004).
- Surendran A (2004). US NIH draft guidelines threaten diagnostics sector. *Nature Biotechnology*, 2004, 22(5):496.
- Suter SM (2001). The allure and peril of genetics exceptionalism: Do we need special genetics legislation? *Washington University Law Quarterly*, Fall 2001, 79(3):669–748.
- Terry SF, Boyd CD (2001). Researching the biology of PXE: Partnering in the process. *American Journal of Medical Genetics*, Fall 2001, 106(3):177–184.
- The International HapMap Consortium (2003). The International HapMap Project. *Nature*, 2003, 426:789–96.

- Thorold C (2001). Indian firms embrace biotechnology. *BBC News Online*, 6 April 2001 ([http://news.bbc.co.uk/1/low/world/south\\_asia/1264569.stm](http://news.bbc.co.uk/1/low/world/south_asia/1264569.stm), accessed 20 February 2004).
- Thorsteinsdóttir H et al. (2003). Genomics—a global public good? *Lancet*, 2003, 361:891–2.
- Trafford A (2001). California vintners put hopes in Brazil's labs. *Washington Post*, 29 December 2001:A01.
- UNDP (1999). Globalization with a human face. New York, United Nations Development Programme, 1999.
- UNESCO (1997). *Universal Declaration on Human Rights and the Human Genome*. UNESCO, Paris, 1997.
- USPTO (2004). *Revised interim utility guidelines training materials, 2004*. United States Patent and Trademark Office (<http://www.uspto.gov/web/menu/utility.pdf>, accessed 8 July 2004).
- Venter C et al. (2001). The sequence of the human genome. *Science*, 16 February 2001, 291(5507):1304–1351.
- Verma IC et al. (2003). Genetic counselling and prenatal diagnosis in India—Experience at Sir Ganga Ram Hospital. *Indian Journal of Pediatrics*, April 2003, 70(4):293–297.
- Verma P, Sharma YD (2003). Malaria genome project and its impact on disease. *Journal of Vector Borne Diseases*, March–June 2003, 40(1–2):9–15.
- Walsh JP, Arora A, Cohen WM (2003). Effects of research tool patents and licensing on biomedical innovation. In: Cohen WM, A Merrill, eds, *Patents in the knowledge-based economy*. Washington, DC, The National Academies Press, 2003:285–340.
- Wang Y (2001). Monsanto under fire for “pirating” Chinese soy strain. *China Daily*, 30 October 2001.
- Waterston RH et al. (2002). Initial sequencing and comparative analysis of the mouse genome. *Nature*, 2002, 420(6915):520–562.
- WHO (1964). *Human genetics and public health. Second report of the WHO Expert Committee on Human Genetics*. Geneva, World Health Organization (WHO Technical Report Series No. 282).
- WHO (1994). *Guidelines for the control of haemoglobin disorder*. Geneva, World Health Organization (WHO/HDP/HB/GL/94.1).
- WHO (1996). *Control of hereditary diseases*. Geneva, World Health Organization (WHO TSR, no. 865:1–86).
- WHO (1998). *Proposed international guidelines on ethical issues in medical genetics and genetic services*. Geneva, World Health Organization (WHO/HGN/GL/ETH/98.1).
- WHO (1999). *Report of a WHO/WAO meeting on prevention and care of genetic disease and birth defects in developing countries*. Geneva, World Health Organization (WHO/HGN/WAOPBD/99/1).
- WHO (2000). *Report of a WHO meeting on public health approaches for the control of genetic disorders*. Geneva, World Health Organization (WHO/HGN/WG/00.1).
- WHO (2002). *Genomics and World Health*. Geneva, The Advisory Committee on Health Research of the World Health Organization, 2002 ([http://www3.who.int/whosis/genomics/pdf/genomics\\_report.pdf](http://www3.who.int/whosis/genomics/pdf/genomics_report.pdf), accessed 12 January 2004).

- Wickelgren I (2004). Heart disease: Gene suggests asthma drugs may ease cardiovascular inflammation. *Science*, 13 February 2004, 303(5660):941.
- Wilson RK (1999). How the worm was won. The *C. elegans* genome sequencing project. *Trends in Genetics*, 1999, 15(2):51–58.
- Wirth D (2001). *A harvest not yet reaped: Genomics to new drugs in Leishmania and Trypanosomes*. Boston, MSF/DND Working Group, September 2001.
- WTO (2001). Ministerial Declaration. WTO/MIN(01)/DEC/2, 20 Nov 2001. Doha, Qatar ([http://www.wto.org/english/thewto\\_e/minist\\_e/min01\\_e/mindecl\\_e.pdf](http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_e.pdf)).
- WTO (2003). Decision removes final patent obstacle to cheap drug imports. *WTO Press Release*, 30 August 2003 (Press/350/Rev.1).
- Yoon CK (2000). Agriculture takes its turn in the genome spotlight. *New York Times*, 18 July 2000.
-